JP Morgan Chase’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

JP Morgan Chase’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-804	Closed	–	–	6065
2019 Q3	$0	Buy	804 +22	+3%	+$15	﹤0.01%	6101
2019 Q2	$1K	Sell	782 -3,157	-80%	-$4.94K	﹤0.01%	5727
2019 Q1	$9K	Sell	3,939 -15,143	-79%	-$41K	﹤0.01%	5562
2018 Q4	$44K	Buy	19,082 +5,720	+43%	+$50.4K	﹤0.01%	5131
2018 Q3	$198K	Buy	13,362 +3,831	+40%	+$60.9K	﹤0.01%	4692
2018 Q2	$145K	Buy	9,531 +4,790	+101%	+$81.3K	﹤0.01%	4702
2018 Q1	$89K	Buy	4,741 +1,225	+35%	+$21.4K	﹤0.01%	4630
2017 Q4	$64K	Buy	3,516 +1,816	+107%	+$38.4K	﹤0.01%	4814
2017 Q3	$38K	Buy	+1,700	New	+$37.3K	﹤0.01%	4526

Other funds holding SNNA

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Private Ocean San Rafael, California $1.13B AUM 11.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase's SNNA Position: Q4 2019 in Review

JP Morgan Chase sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2019, closing a stake of 804 shares.

JP Morgan Chase first reported a position in SNNA in Q3 2017 and held it in 9 quarters. The position peaked at $198K in Q3 2018. 4 funds tracked by Wall St. Rank hold SNNA as of Q4 2019.

JP Morgan Chase reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
JP Morgan Chase sold 804 Sienna Biopharmaceuticals, Inc. shares in Q4 2019.
JP Morgan Chase first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 9 quarters.
JP Morgan Chase's Sienna Biopharmaceuticals, Inc. position peaked at $198K in Q3 2018.
4 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2019.

Based on JP Morgan Chase's 13F filing for Q4 2019, filed 11 Feb 2020.